RFK Jr. is overhauling the program that helps preserve Americans' access to vaccines

HHS Secretary Robert F. Kennedy Jr. is pushing to overhaul the Vaccine Injury Compensation Program by broadening the injury table and potentially redefining 'encephalopathy' to cover some autism-like conditions, a change that would allow retroactive filings; the program's trust fund currently sits at just over $4 billion. Industry and public-health experts warn expanded eligibility and longer filing windows — against a backdrop of CDC advisory committee changes and potential DOJ involvement — could trigger thousands of lifetime-care claims (CDC: ~1 in 31 eight‑year‑olds diagnosed with autism), bankrupt the fund, drive small vaccine manufacturers from the U.S. market and chill investment in new vaccines. The proposal increases legal and regulatory risk for vaccine makers and investors and raises the prospect of substantial downstream payouts, legislative fights, and further erosion of market confidence in U.S. vaccine policy.

Analysis

Market structure: Short-term winners are plaintiffs’ lawyers and alternative-care providers who could see near-term fee flow; losers are small and mid‑cap vaccine makers and contract manufacturers whose liability, funding and go‑to‑market calculus are most sensitive to table expansion. Fewer suppliers would raise negotiation leverage for incumbent diversified pharmas (Pfizer, J&J) but overall price power is muted because many vaccines are government‑procured contracts; expect procurement and margin pressure in providers, higher bid‑ask volatility for vaccine equities over 30–90 days.

Risk assessment: Tail risks include (A) an expanded table triggering thousands of autism‑related claims that deplete the ~$4bn trust fund within 1–3 years, prompting emergency congressional fixes or litigation, and (B) courts or regulatory shifts removing preemption and inviting mass torts; both would materially widen credit spreads for niche vaccine firms (>200–500bps) and push implied vol for biotech up 30–80%. Immediate market reactions will occur in days around HHS/ACIP announcements; medium term (3–9 months) R&D investment freezes; long term (1–3 years) structural consolidation or repatriation of manufacturing.

Trade implications: Tactical defensive posture: favor large-cap diversified pharma and healthcare staples, hedge biotech exposure with puts or credit protection. Direct plays: buy 3‑month 12–18% OTM puts on MRNA sized to 1–2% portfolio risk ahead of HHS release; establish a 1–2% long in PFE/JNJ vs 1% short in MRNA as a pair over 3–6 months. Use 3‑6 month long‑dated put spreads on small vaccine names or buy IBB downside (hedged) to capture sector repricing.

Contrarian angles: Consensus may be overstating permanent exit risk — 1986 precedent shows legislative fixes and program tweaks tend to stabilize markets, not kill them. If HHS limits changes to narrow encephalopathy definitions and Congress increases special masters or award caps, the selloff is likely overdone; look for recovery signals: (1) HHS draft restricts onset windows to <24 months, or (2) Congress allocates +$1–2bn to the trust fund — these would be buy signals for selected beaten down names.

Key Decisions for Investors

• Buy 3‑month puts on MRNA sized to 1–2% of portfolio risk (pick 12–18% OTM strikes) within the next 14 days to hedge regulatory‑table expansion risk ahead of HHS/ACIP actions; target a 30–50% profit or cut at 50% time decay loss.
• Initiate a 3–6 month pair trade: long 1–2% position in PFE or JNJ (diversified vaccine exposure) financed by a 1% short position in MRNA to capture relative safety; rebalance if MRNA moves >25% intraday or after HHS proposal release.
• Reduce exposure to small‑cap vaccine/contract manufacturers by 30–50% and purchase credit protection (or long CDS where available) sized to cover potential spread widening of 300–500bps over 3–12 months; prioritize companies with <2 years of cash runway.
• Deploy a sector hedge: buy IBB downside protection via a 4–6 month put spread (limit premium to 0.5–1% portfolio) to capture broad biotech implied‑volatility expansion; unwind if HHS language restricts table changes to <24 months onset or if Congress injects >$1bn to the trust fund within 90 days.